MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 29.11.2025
Aptorum Group Limited Langfristiger Schuldenstrom 2011-2025 | APM
Langfristiger Schuldenstrom Jährlich Aptorum Group Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 433 K | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 433 K | 433 K | 433 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
178 M | $ 223.01 | -0.99 % | $ 395 B | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
481 K | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
AstraZeneca PLC
AZN
|
339 M | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
1.6 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
86.4 M | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
BioVie
BIVI
|
74.5 K | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Baudax Bio
BXRX
|
5.6 M | - | 0.59 % | $ 63 K | USA |
 |
Catalyst Biosciences
CBIO
|
210 K | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
ChromaDex Corporation
CDXC
|
982 K | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
9.45 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Cerus Corporation
CERS
|
2.28 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Caladrius Biosciences
CLBS
|
137 K | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.45 M | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Cellectar Biosciences
CLRB
|
59 K | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 0.29 | -5.01 % | $ 631 M | Israel |
 |
Cortexyme
CRTX
|
64 K | - | -1.05 % | $ 67.1 M | USA |
 |
Benitec Biopharma
BNTC
|
354 K | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
19 M | $ 60.38 | 0.11 % | $ 6.76 M | USA |
 |
BioNTech SE
BNTX
|
39.5 M | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.18 M | $ 10.89 | -0.09 % | $ 1.42 B | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
712 K | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |